TOKYO, Sept. 16, 2025 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation […]
TOKYO and CAMBRIDGE, Mass., Oct. 31, 2024 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that […]
-Eisai Initiates Phase II Clinical Study on Sporadic Early Alzheimer’s Disease- TOKYO, Oct. 30, 2024 /PRNewswire/ — Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest findings on anti-MTBR (microtubule […]
